Clinical Trials

Photo: Clinical Trials


Fat-derived Mesenchymal Stem-Cell Therapy for Cats with Chronic Gingivostomatitis

Purpose of Study: Feline chronic gingivostomatitis (FCGS) is a poorly defined disease characterized by inflammatory lesion, mostly ulcerative or proliferative in nature, affecting the gums and the back of the mouth. Moreover, FCGS is a painful and debilitating disease in cats that necessitates medical or surgical treatments. These include full-mouth extractions, antibiotic treatment, and corticosteroids. Recently, feline interferon treatment (currently unavailable in the USA) has been proposed for non-responsive stomatitis. However, none of these treatments are ideal, predictable and without possible complications. The quality of life to both pet and owner is significantly affected.

A form of stem cell therapy where stem cells are extracted from fat tissue has come to the forefront in recent years as a potential therapeutic option for chronic inflammatory diseases. This cell therapy may help to correct abnormalities of the immune system that may be involved with stomatitis in cats. Moreover, stem cells are shown to help in regenerating damaged tissues. Feline stem cells has shown to be easily generated in large quantities from a small amount of fat collected via minor surgical procedure but safely of systemic administration in cats was not reported previously.

In this study, our aim is to treat cats in which all current treatment modalities have failed and that have a poor quality of life. If the proposed stem cell treatment will prove to be beneficial, it may revolutionize the treatment options for cats with FCGS.

Photo: Clinical Trials


Immunomodulation by Mesenchymal Stem Cells In Canine Inflammatory Bowel Disease

Purpose of Study: Inflammatory bowel disease (IBD) in dogs often involves lifelong steroid therapy, which holds the risk for a variety of potentially serious complications. Because of the ability to regulate immune responses and facilitate tissue regrowth or repair, we believe that fat-derived, mesenchymal stem cells (MSCs) may help to decrease the abnormal immune response and the accompanying inflammation. Therefore, the purpose of this study is to investigate the effectiveness of a new stem cell therapy for canine IBD and better understand how stem cells work to limit inflammation and repair gut tissue.

Photo: Clinical Trials


Efficacy of Autologous Mesenchymal Stem Cells for Treatment of Equine Recurrent Uveitis Following Intravenous Injection

Purpose of Study: Equine recurrent uveitis (ERU) is caused by inflammation of the uveal tract of the eye and is the most common cause of blindness in horses. ERU often involves lifelong medical therapy or surgery, which holds the potential for a variety of potentially serious complications. Because fat-derived stem cells are known to regulate inflammation and facilitate tissue repair, we wish to investigate the effectiveness of a new stem cell therapy for ERU and to better understand how stem cells work to limit inflammation. This treatment has the potential for being relatively non-invasive and removing the need for lifelong treatment.

Veterinary Center for Clinical Trials

Visit the Veterinary Center for Clinical Trials